The Cigna Group (CI) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is broadly balanced-to-slightly-positive — consensus is a manageable bar, management guided explicitly for Q2 MCR to be "slightly above the high end" of the full-year range (implying ~85%+), and the biggest swing factor is whether commercial medical cost trends have stabilized or are still creeping higher, as flagged by UNH.

Heading into Q2 2026, Cigna's bar is well-telegraphed: management guided Q2 adjusted EPS at approximately 25% of the full-year $30.35 floor (implying ~$7.59), and consensus sits at $7.60 — essentially at the guidance midpoint with minimal cushion. The MCR is the key swing factor: management explicitly guided Q2 MCR to be "slightly above the high end" of the 83.7%–84.7% full-year range, meaning the market is braced for a step-up from Q1's unusually favorable 79.8% (driven by weather deferrals and a higher bronze mix), and any outperformance vs. that elevated Q2 guide would be a positive surprise. On the Evernorth side, Pharmacy Benefit Services earnings are expected to continue declining year-over-year (~28% in Q1) as large client contract renewals and Signature model investment costs ramp — this is fully in the guide and unlikely to surprise. Specialty & Care Services is the growth engine to watch: Q1 delivered +20% year-over-year growth and management guided to the high end of the growth range for the full year, so any deceleration here would be a negative read. The stock has recovered ~2% since Q1 earnings (April 30) but has lagged XLV meaningfully, trading at a compressed ~9.4x NTM P/E — the multiple tells you the market is still skeptical of the PBM transformation story and stop-loss recovery trajectory. The wildcard is commercial medical cost trend: UNH explicitly called out commercial costs "stubbornly high, rising above expectations" at modestly above 11%, driven by the No Surprises Act IDR process and provider coding intensity — if Cigna's commercial book shows similar pressure, the MCR guide could prove optimistic and the stock could re-test recent lows.

Bar: Consensus at $7.60 is essentially at the guidance floor (~25% of $30.35), making it a low-to-fair bar — not a high hurdle, but with limited room for upside surprise given the explicit Q2 MCR warning.

Guidance/Tone: Management tone has been steady and confident since Q1 — the May 13 8-K reaffirmed full-year EPS of at least $30.35, and the BofA Healthcare Conference commentary (also May 13) noted "so far, so good for April" with no variability vs. outlook. New CEO Brian Evanko (effective July 1) has maintained the same strategic messaging; Investor Day is planned for September 2026.

Estimate Trajectory: Q2 consensus has been remarkably stable — estimates moved from $7.59 (as of May 7) to $7.60 currently, essentially flat. FY2026 consensus is similarly anchored at $30.40, just above the $30.35 guidance floor. Revisions are tracking guidance, not diverging — no gap risk or cushion.

Stock Setup: CI is up ~2% since Q1 earnings but has significantly underperformed XLV (+14%) over the same period. At ~9.4x NTM P/E, the stock is pricing in continued execution risk around the PBM transformation — a clean beat with stable MCR and specialty growth at the high end could catalyze multiple re-rating.

Wildcard: Commercial medical cost trend. UNH flagged commercial costs "stubbornly high" at 11%+ driven by the No Surprises Act IDR process (adding ~100 bps of total cost) and provider coding intensity. If Cigna's commercial book shows similar acceleration, the Q2 MCR could breach the high end of the full-year range and force a guidance revision — the single biggest downside risk to the print.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a fair-to-low bar at the guidance floor on EPS; the MCR is the bigger swing factor given the explicit Q2 step-up guide, while Specialty & Care Services income growth is the upside lever if biosimilar adoption and volumes continue to outperform.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 29, 2026. Guidance references from Q1 2026 Earnings Call (April 30, 2026) and Bank of America Global Healthcare Conference (May 13, 2026).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Adj. EPS & MCR)

Adjusted EPS (Diluted Operating)

Medical Care Ratio — Cigna Healthcare (%)

Pattern: CI has beaten EPS consensus in 7 of the last 8 quarters, with the sole miss being Q4 2024 (the stop-loss shock quarter). On MCR, the pattern is more mixed — Q4 2024 and Q4 2025 were meaningful misses, while Q1 2026 was a significant beat driven by one-time weather/respiratory favorability that management explicitly guided will reverse in Q2. The Q2 2026 MCR consensus of 84.6% sits below management's own guidance signal of "slightly above the high end" (~85%+), suggesting the street may be underestimating the seasonal step-up.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been stable since Q1 earnings — the May 13 8-K reaffirmed the $30.35 FY EPS floor with no changes; the only post-earnings update was a constructive tone at the BofA Healthcare Conference noting April was tracking to plan. No guidance has been revised upward or downward since the Q1 print.

Sources: Q1 2026 Earnings Call Transcript (April 30, 2026); CI 8-K filed May 13, 2026 (EPS reaffirmation); Bank of America Global Healthcare Conference transcript (May 13, 2026); Visible Alpha Consensus Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since Q1 earnings — Q2 EPS consensus moved only +$0.01 and FY2026 EPS moved only +$0.01 from the post-Q1 baseline, confirming the street is anchored to guidance with no independent revision momentum in either direction. The gap between consensus and guidance is minimal, leaving little cushion.

Estimates are tracking guidance with near-zero revision momentum since the Q1 print. The only notable divergence is on Q2 MCR, where consensus (84.6%) sits below management's own guidance signal (~85%+) — this gap represents a modest risk that the reported MCR comes in above consensus even if it meets management's guidance. FY2027 EPS has drifted slightly lower (-0.5%) since the Q1 baseline, reflecting no formal guidance and lingering uncertainty around the PBM transformation timeline.

Source: Visible Alpha Consensus and Actuals Data. Post-Q1 baseline as of May 7, 2026 (5 trading days after April 30, 2026 earnings).

5. Stock Performance

Key Takeaway: CI has significantly underperformed XLV since Q1 earnings (+2% vs. +14% for XLV), with the gap driven almost entirely by multiple compression — the stock's NTM P/E has barely moved while the sector re-rated sharply higher on improving managed care sentiment (UNH's Q2 beat, CNC's guidance raise). CI's lagging performance reflects persistent skepticism around the PBM transformation and stop-loss recovery, not deteriorating fundamentals.

Since Q1 2026 earnings (April 30, 2026), CI has returned approximately +2.0% (from $290.58 to $296.47 as of July 29, 2026), meaningfully lagging XLV (+13.9%, from $145.99 to $166.24) and roughly in line with SPY (+1.5%, from $718.66 to $729.46). The stock's underperformance vs. XLV is notable given that the broader managed care sector has re-rated sharply higher on improving medical cost trend signals from UNH (Q2 beat, July 16) and CNC (guidance raise, July 28). CI's NTM P/E has expanded modestly from ~8.9x to ~9.4x over the period, but the multiple remains deeply discounted vs. historical levels and peers, reflecting the market's continued skepticism about the multi-year PBM transition and the pace of stop-loss margin recovery. Key events during the period include: the May 13 EPS reaffirmation (modest positive), the BofA Healthcare Conference (constructive tone, no change), and the July 1 CEO transition to Brian Evanko. The stock's recent rally from ~$270 in early June to ~$301 on July 28 (before pulling back to $296 on July 29) appears to reflect sector-wide managed care re-rating rather than CI-specific catalysts.

Current Valuation: NTM P/E of 9.4x (vs. ~9.4x at Q1 earnings) — essentially flat multiple expansion since Q1, with the stock's modest gain driven entirely by slight EPS estimate stability rather than re-rating. EV/EBITDA of 8.3x. The stock trades at a significant discount to the managed care peer group, reflecting PBM transformation risk premium.

Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition Data.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the CEO transition to Brian Evanko (effective July 1), which sets the stage for the September 2026 Investor Day as the next major strategic catalyst. The May 13 EPS reaffirmation removed near-term guidance risk, and the July 23 AI announcement is a positive incremental signal on medical cost management.

• July 23, 2026 — Cigna AI Medical Cost Savings Announcement: Cigna announced its AI tools designed to identify patients with chronic or complex conditions will save customers $200 million in medical costs over the next three years. Bryan Holgerson (President, Cigna Healthcare) stated the technology will boost clinical access by 20% for people with conditions like cancer, heart, and kidney disease, and that customers using these clinical programs save $2,000/year in medical costs. Implication: Positive incremental signal on medical cost management capabilities heading into Q2 print; reinforces management's AI-driven stop-loss and care management narrative.
• July 1, 2026 — CEO Transition: Brian Evanko Succeeds David Cordani: Brian Evanko officially became CEO on July 1, 2026, with David Cordani transitioning to Executive Chair. Evanko has been President and COO and is the architect of the Evernorth growth strategy. Implication: Leadership continuity is the base case; the September 2026 Investor Day will be Evanko's first major strategic platform and is the next key catalyst for multiple re-rating.
• May 13, 2026 — Full-Year 2026 EPS Reaffirmation (8-K): Cigna filed an 8-K reaffirming projected full-year 2026 consolidated adjusted income from operations of at least $30.35 per share, consistent with Q1 earnings guidance. Implication: Removed near-term guidance cut risk; confirmed April tracking to plan. Modest positive for sentiment.
• May 13, 2026 — BofA Global Healthcare Conference: Management noted "so far, so good for April" with no variability vs. outlook across both Cigna Healthcare and Evernorth. Confirmed cost trends remain elevated but not accelerating. Provided additional color on the Signature PBM model transition timeline (standard model in 2028, at least 50% of members by year-end 2028) and stop-loss repricing cadence (2/3 in 2026, 1/3 in 2027). Implication: Constructive tone; no negative surprises. Reinforced Q2 setup as tracking to plan.
• April 30, 2026 — Q1 2026 Earnings: Two Portfolio Shaping Actions Announced: (1) Exit of individual exchange business at end of 2026; (2) Initiation of strategic review of eviCore (prior authorization services unit). Management framed both as proactive portfolio shaping to focus on three core growth platforms. Implication: Ongoing — eviCore strategic review outcome is a potential catalyst (sale/spin could unlock capital); individual exchange exit removes a loss-making segment from 2027 financials.
• April 27, 2026 — Annual Meeting: Shareholders Reject Written Consent Proposal: Cigna shareholders rejected a written consent proposal and approved directors and executive pay. Implication: No governance disruption; routine outcome.

7. Peer Commentary & Read-Throughs (Last 60 Days)

Scope Note: This section includes only commentary made during Q2 2026 earnings calls (reporting Q2 results) or post-Q1 conference appearances explicitly addressing Q2/current-quarter trends or the balance of 2026. Commentary limited solely to peers' prior-quarter (Q1) results is excluded. All four peers below reported Q2 2026 results in July 2026 and provided forward-looking commentary directly relevant to Cigna's Q2 2026 print.

7.1 UnitedHealth Group (UNH) — Q2 2026 Earnings Call (July 16, 2026)

Relevance: UNH is the largest managed care peer and the most direct read-through for commercial medical cost trends, Medicare Advantage, and PBM (Optum Rx). UNH's Q2 results beat expectations and the company raised FY2026 EPS guidance to $19.50–$20.00, with the full-year MCR now guided at 88.1% ±25 bps.

• Commercial Medical Costs — Negative Read-Through for CI: UNH stated commercial costs are "stubbornly high, rising above expectations, which we believe is consistent with what is being experienced across the sector." Commercial medical cost trends are running at "modestly above 11%." The primary drivers are (1) the No Surprises Act IDR process, contributing "50 basis points or so of incremental trend in 2026, now totaling at least 100 basis points of total cost," and (2) provider coding intensity in office visits, emergency departments, and other care sites. UNH explicitly noted "we are not yet seeing evidence of cost trend moderation. In fact, it is the opposite." Commercial margin recovery is now expected to extend "past 2027." CI Read-Through: This is the most important negative read-through for Cigna's Q2 MCR. Cigna's commercial employer book is its largest segment, and if the IDR process and coding intensity are sector-wide phenomena (as UNH stated), Cigna's Q2 MCR could come in at or above management's own guidance signal of "slightly above the high end" of the 83.7–84.7% range.
• Medicare Advantage — Positive Read-Through for CI: UNH reported Medicare medical cost trends "still running well above historical levels, but below our expectations so far in 2026," with the full-year Medicare trend now expected to come in below the initial ~10% estimate. UNH attributed this to its own initiatives (benefit design, care management, network curation) as well as a more favorable respiratory season. CI Read-Through: Positive for Cigna's Medicare Advantage business. If the favorable respiratory/weather dynamic that benefited Cigna's Q1 MCR has partially persisted into Q2 for Medicare, it could provide some offset to commercial cost pressure.
• PBM / Optum Rx — Competitive Context for Evernorth: Optum Rx is "performing to plan" and UNH expects to end 2026 with "more than 95% of clients on 100% pass-through" of manufacturer rebates. UNH announced a new pharmacy care approach based on monthly per-member fees with full PBM and GPO fee transparency. Client feedback has been "positive." CI Read-Through: Confirms the industry-wide shift toward transparency and fee-based PBM models, validating Cigna's Signature model strategy. However, Optum Rx's strong execution and high retention rates (high 90s) also confirm that Cigna faces a formidable competitor in the 2027 PBS selling season.
• AI & Prior Authorization — Competitive Benchmark: UNH committed to processing "80% of prior authorizations in real time by end of 2027" and is eliminating 30% of prior authorization volume by year-end 2026. Digital prior auth powered by AI is producing "96% first pass approval." CI Read-Through: Sets a high bar for Cigna's eviCore strategic review — if prior authorization is increasingly automated and commoditized, the strategic rationale for retaining eviCore as a standalone asset weakens, potentially accelerating a sale or spin.

7.2 Elevance Health (ELV) — Q2 2026 Earnings Call (July 15, 2026)

Relevance: ELV is the most direct commercial employer peer and has a significant integrated medical/pharmacy model (Carelon) comparable to Cigna's Evernorth. ELV beat Q2 expectations and raised FY2026 EPS guidance to at least $27, driven by favorable benefit expense performance in Medicare Advantage and individual ACA.

• Commercial Employer Trends — Mixed Read-Through for CI: ELV reported commercial group performance "in line with expectations, with cost trend remaining elevated but consistent with the pricing approach we have taken." The bulk of ELV's commercial business is fee-based or self-funded, performing "incredibly well." Persistency and sales rates are climbing, and some customers who left 2–3 years ago have returned. CI Read-Through: Constructive for Cigna's commercial ASO/self-funded book. The market for integrated medical and pharmacy solutions is resonating, which aligns with Cigna's Evernorth value proposition. However, ELV's "elevated but consistent with pricing" language suggests cost trends remain a headwind even for well-managed books.
• Medical Cost Drivers — Negative Read-Through for CI: ELV identified cost drivers as "elevated and concentrated in behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization" and stated its outlook assumes "this elevated operating environment persists through the balance of the year." ELV is "not seeing a new stepwise acuity reset" but pressure is increasingly from utilization among existing members. CI Read-Through: Confirms the persistence of elevated cost trends across the sector. The specific call-out of specialty pharmacy as a key cost driver is relevant for Cigna's MCR management, though Cigna's Evernorth PBM position gives it tools to manage specialty costs that pure health plan peers lack.
• Individual ACA — Positive Read-Through for CI: ELV reported ACA trend "very much in line to slightly favorable for the second quarter," supported by favorable volume and timing dynamics and a more bronze plan orientation. ELV now expects to end 2026 with at least 1 million individual ACA members. CI Read-Through: Positive for Cigna's individual exchange business (which it is exiting at year-end 2026). A favorable ACA environment in Q2 could provide a modest tailwind to Cigna's exchange MCR, partially offsetting commercial pressure.
• Integrated Medical/Pharmacy Model — Positive Read-Through for Evernorth: ELV's Carelon health services arm is "becoming an increasingly important and durable driver of enterprise growth," with strong demand for its integrated medical and pharmacy offering in the 2027 selling season. Carelon is expanding into behavioral health and oncology. CI Read-Through: Validates the secular demand for integrated health services, directly supporting Cigna's Evernorth Specialty & Care Services growth thesis. The oncology expansion by ELV also highlights the competitive opportunity in a space where Cigna has acknowledged having "less meaningful presence relative to peers."

7.3 Centene Corporation (CNC) — Q2 2026 Earnings Call (July 28, 2026)

Relevance: CNC is a major Evernorth/Express Scripts client (leveraging $60B+ in pharmacy spend through ESI) and a key read-through for PBM competitive dynamics and Medicaid cost trends. CNC reported a strong Q2 beat and raised FY2026 EPS guidance to greater than $4.80 (from $3.40), driven by improved Marketplace and PDP margins.

• ESI/PBM Partnership — Direct Positive Read-Through for Evernorth: CNC explicitly highlighted leveraging "greater than $60 billion in pharmacy spend through our partnership with ESI to deliver industry-leading cost structure." CNC's Medicare Part D (PDP) business is now expected to deliver a pre-tax margin of greater than 3% in 2026 (vs. 2% initial guidance), attributed to strong execution, product positioning, and being "another year removed from the inception of the Inflation Reduction Act." CI Read-Through: Directly positive for Evernorth's PBS segment. CNC's improved PDP margin and explicit credit to the ESI partnership validates Cigna's PBM value proposition and suggests the ESI-CNC contract (one of the three large client renewals) is performing well operationally, even if economics were reset at renewal.
• Specialty Drug Trend — Positive Read-Through for Evernorth Specialty: CNC noted elevated specialty drug trends in PDP but "lower than original expectations through the first half of the year." The IRA's impact on utilization (triggering additional specialty utilization as members hit out-of-pocket caps) is being tracked closely. CI Read-Through: Positive for Cigna's Specialty & Care Services segment. If specialty drug volumes are elevated but below initial fears, Accredo's specialty pharmacy volumes should remain robust while biosimilar adoption (HUMIRA, STELARA, Revlimid generics) continues to drive margin improvement.
• Medicaid Cost Trends — Indirect Read-Through: CNC reported Medicaid medical cost trend "remained stable and consistent with full year guidance of 5%," with behavioral health showing "a second quarter of year-over-year moderation." Medicaid rates improved to ~5% composite (from 4.5%), with the July 1 rate cohort coming in strong. CI Read-Through: Limited direct relevance given Cigna's small Medicaid footprint, but the stabilization of Medicaid trends and improving rate environment is a broadly positive signal for the managed care sector.
• AI & Operational Efficiency — Competitive Context: CNC is shifting its AI strategy from individual use cases to foundational capabilities (trusted data products, dynamic context management), with specific applications in forecasting, fraud/waste/abuse detection, and legal invoice review (saving 1.5 points on legal bills monthly). CI Read-Through: Confirms the industry-wide investment in AI for operational efficiency. Cigna's own AI announcements (July 23 medical cost savings, AI-driven customer service) are consistent with this trend.
• Guidance Raise — Sector Sentiment Positive: CNC raised FY2026 EPS guidance to greater than $4.80 (from $3.40), a massive $1.40+ raise driven by improved Marketplace and PDP performance. The stock surged on the news (July 28). CI Read-Through: Positive sector sentiment heading into CI's July 30 print. The managed care sector is broadly re-rating on improving cost trend signals, which could provide a favorable backdrop for CI's results even if the print itself is in-line.

7.4 Molina Healthcare (MOH) — Q2 2026 Earnings Call (July 22–23, 2026)

Relevance: MOH is primarily a government-managed care peer (Medicaid/Medicare Duals) with limited direct read-through to Cigna's commercial book, but provides useful color on pharmacy cost trends and Medicare Duals performance. MOH reported lower Q2 profit and revenue, with Marketplace segment significantly underperforming.

• Medicaid Cost Trend Stabilization — Modest Positive Read-Through: MOH reported Medicaid medical cost trend "remained stable and consistent with full year guidance of 5%," with the trend having "plateaued." High-trend categories (behavioral health, professional office visits, inpatient) are "expected to remain stable in the second half." CI Read-Through: Limited direct relevance (Cigna's Medicaid exposure is small), but the stabilization narrative is broadly constructive for the sector.
• Medicare Duals Pharmacy Trend — Positive Read-Through for Evernorth: MOH's Medicare Duals products performed better than expected in Q2, with the pharmacy category coming in better across the board (inpatient, outpatient, ancillary, and pharmacy). The full-year Medicare MCR guidance was improved by 180 bps, with duals trend now forecast at 4% (vs. initial 6%). CI Read-Through: Positive for Cigna's PBM and Medicare Advantage businesses. Favorable pharmacy trends in Medicare Duals suggest effective cost management in the government pharmacy channel, which is relevant for Express Scripts' Medicare Part D book.
• Marketplace Acuity Issues — Negative Read-Through for CI's ACA Exit: MOH reported significant Marketplace underperformance due to "unfavorable current year member acuity mix" and "high cost drug utilization without corresponding HCC to drive risk adjustment." MOH raised its Marketplace MCR guidance from 85.5% to 90% and now expects a full-year Marketplace loss of $0.75/share. MOH plans to reduce Marketplace exposure by ~$1B in 2027. CI Read-Through: Validates Cigna's decision to exit the individual exchange business at year-end 2026. The acuity and risk adjustment challenges MOH is experiencing are consistent with the structural difficulties Cigna cited in its exit decision ("no clear path to scale"). However, ELV's more favorable ACA experience suggests the impact may be company-specific rather than universal.

Peer Commentary Summary Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys from insiders since Q1 earnings — the only transactions are a large 10b5-1 planned sale by outgoing CEO David Cordani (May 12) and a small discretionary sale by the Chief Accounting Officer (June 12). The Cordani sale is obligation-driven and not a signal; the CAO sale is immaterial in size. No clustered buying or unusual activity to flag.

No open-market purchases by any insider since Q1 earnings. The absence of insider buying at a stock trading at a multi-year valuation discount (~9.4x NTM P/E) is notable but not alarming — the CEO transition and pre-earnings blackout window likely constrain discretionary activity. The Cordani 10b5-1 sale is a routine pre-planned transaction with no informational content.

Source: SEC Form 4 Filings Database (Insider Transaction Data).

9. Key Risks & Questions for Management

Key Risks

• Commercial Medical Cost Trend Acceleration (High Risk): UNH explicitly flagged commercial costs "stubbornly high" at 11%+ and sector-wide, driven by the No Surprises Act IDR process (100 bps of total cost) and provider coding intensity. If Cigna's commercial book shows similar dynamics, Q2 MCR could breach the high end of the full-year range and force a guidance revision. This is the single biggest downside risk to the print.
• Q2 MCR Step-Up vs. Consensus Expectations (Medium-High Risk): Management guided Q2 MCR to be "slightly above the high end" of the 83.7–84.7% full-year range (~85%+), but consensus sits at 84.6% — ~40 bps below the guidance signal. The steeper Q1→Q2 seasonality (Medicare exit, higher bronze mix) is well-understood, but the magnitude of the step-up could still surprise negatively if commercial trends are worse than expected.
• PBM Earnings Decline Trajectory (Medium Risk): PBS pretax adjusted earnings declined 28% YoY in Q1 as large client contract renewals and Signature model investment costs ramped. Management guided this trajectory is "consistent with prior commentary," but any acceleration in the decline or commentary suggesting the 2027 selling season is tracking below expectations would be a negative signal for the multi-year recovery thesis.
• eviCore Strategic Review Outcome (Medium Risk): The strategic review of eviCore (prior authorization services) is ongoing with no transaction announced. UNH's commitment to automating 80% of prior authorizations in real time by 2027 and eliminating 30% of prior auth volume by year-end 2026 raises questions about eviCore's standalone value. A sale at a disappointing valuation or a decision to retain the asset could be a negative catalyst.
• CEO Transition Execution Risk (Low-Medium Risk): Brian Evanko's first earnings call as CEO (Q2 2026) will be closely watched for any strategic pivots or tone changes. The September 2026 Investor Day is the next major catalyst, and any signals of strategic uncertainty or changes to the long-term growth algorithm could weigh on the stock.
• Stop-Loss Repricing Completion Risk (Low-Medium Risk): Management has guided stop-loss repricing as ~2/3 complete in 2026 and ~1/3 in 2027. Any indication that the repricing is taking longer than expected or that 2027 stop-loss margins will not recover as guided would push out the earnings recovery timeline.

Questions for Management

1. Commercial Medical Cost Trend: UNH called out commercial costs "stubbornly high" at 11%+ and sector-wide, driven by the No Surprises Act IDR process and provider coding intensity. How is Cigna's commercial book trending relative to your Q2 MCR guidance of "slightly above the high end" of the full-year range? Are you seeing similar IDR-driven pressure, and what is the magnitude?
2. Q2 MCR Drivers: Q1 MCR benefited from weather deferrals, lower flu volumes, and a higher bronze mix. How much of the Q1 favorability reversed in Q2 as guided? Were there any offsetting factors (e.g., favorable respiratory trends in Medicare, as seen by UNH) that moderated the step-up?
3. PBS Earnings Trajectory: PBS earnings declined 28% YoY in Q1 and you guided the trajectory is consistent with prior commentary. Can you confirm the Q2 PBS earnings decline is tracking to the full-year Evernorth guidance of at least $6.9B? Are Signature model investment costs ramping as expected, and is the 2027 selling season still tracking ahead of prior years?
4. eviCore Strategic Review: Can you provide an update on the strategic review of eviCore? Given UNH's commitment to automating 80% of prior authorizations in real time by 2027, how does this change the competitive landscape for eviCore and its standalone value? What is the expected timeline for a decision?
5. Specialty & Care Services Growth: Q1 Specialty & Care delivered +20% YoY growth. Can you confirm Q2 is tracking to the high end of the 8–11% annual growth range? What is the contribution from Shields Health Solutions in Q2, and how is biosimilar adoption (HUMIRA, STELARA, Revlimid generic) trending?
6. September Investor Day Preview: What can investors expect from the September 2026 Investor Day? Will you provide a formal FY2027 EPS target? How should we think about the long-term growth algorithm as the Signature model scales and stop-loss repricing completes?
7. Capital Allocation: You noted 2026 cash flow is expected to be back-half weighted. Can you provide an update on the cadence of share repurchases and deleveraging in H2 2026? How does the eviCore strategic review affect capital allocation priorities?